
Opinion|Videos|July 10, 2024
Improvement in Management of Duchenne Muscular Dystrophy in Recent Years
Author(s)Emma Ciafaloni, MD
A neurologist discusses how recent approvals of therapies for Duchenne muscular dystrophy have improved patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How have these recent approvals improved the management of Duchenne muscular dystrophy (DMD)?
- Share your experience with recent approvals in DMD.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial
2
Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease
3
New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne
4
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials
5












